RS68286B1 - Oftalmološka kompozicija za lečenje bolesti suvog oka - Google Patents
Oftalmološka kompozicija za lečenje bolesti suvog okaInfo
- Publication number
- RS68286B1 RS68286B1 RS20260802A RSP20260802A RS68286B1 RS 68286 B1 RS68286 B1 RS 68286B1 RS 20260802 A RS20260802 A RS 20260802A RS P20260802 A RSP20260802 A RS P20260802A RS 68286 B1 RS68286 B1 RS 68286B1
- Authority
- RS
- Serbia
- Prior art keywords
- composition
- pharmaceutical composition
- dry eye
- cyclosporine
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
- A61J1/06—Ampoules or carpules
- A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/1468—Containers characterised by specific material properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Claims (15)
1. Patentni zahtevi
1. Farmaceutska kompozicija za upotrebu u lečenju bolesti suvog oka kod humanog subjekta koji pati od bolesti suvog oka, pri čemu kompozcija sadrži oko 0,1% (mas/v) ciklosporina rastvorenog u 1-perfluorobutilpentanu, i pri čemu se jedna doza kompozicije lokalno primenjuje dva puta dnevno kao samo jedna kap od oko 10 µl u oko subjekta.
2. Farmaceutska kompozicija za upotrebu u lečenju oštećenja očne površine kod humanog subjekta koji pati od bolesti suvog oka, pri čemu kompozicija sadrži oko 0,1% (mas/v) ciklosporina rastvorenog u 1-perfluorobutilpentanu, i pri čemu se jedna doza kompozicije lokalno primenjuje dva puta dnevno kao samo jedna kap od oko 10 µl u oko subjekta.
3. Farmaceutska kompozicija za upotrebu u smanjenju oštećenja površine oka kod humanog subjekta koji pati od bolesti suvog oka, pri čemu kompozicija sadrži oko 0,1% (mas/v) ciklosporina rastvorenog u 1-perfluorobutil-pentanu, i pri čemu se jedna doza kompozicije lokalno primenjuje dva puta dnevno kao samo jedna kap od oko 10 µl u oko subjekta.
4. Farmaceutska kompozicija za upotrebu prema patentnim zahtevima 2 do 3, pri čemu je oštećenje površine oka izabrano od oštećenja rožnjače i/ili konjunktive.
5. Farmaceutska kompozicija za upotrebu prema bilo kom prethodnom patentnom zahtevu, pri čemu je kompozicija bistar rastvor i uglavnom ne sadrži vodu i/ili je uglavnom bez konzervansa.
6. Farmaceutska kompozicija za upotrebu prema bilo kom prethodnom patentnom zahtevu, pri čemu je bolest suvog oka umerena do ozbiljna bolest suvog oka.
7. Farmaceutska kompozicija za upotrebu prema bilo kom prethodnom patentnom zahtevu, pri čemu se kompozicija primenjuje kod subjekta koji ne reaguje na lečenje veštačkim suzama.
8. Farmaceutska kompozicija za upotrebu prema patentnom zahtevu 6, gde je subjekt koji se leči karakterisan najmanje jednim ili kombinacijom:
i.) ukupni rezultat bojenja rožnjače fluoresceinom od najmanje jednakog ili većeg od 6, pri čemu je rezultat zbir rezultata dobijenih za donje, gornje, centralne, nazalne i privremene regione rožnjače, na osnovu NEI skale ocenjivanja od 0‑3;
ii.) simptomatski, poželjno sa rezultatom jednakim ili većim od 40 na vizuelnoj analognoj skali suvoće (VAS);
iii.) rezultat jednak ili veći od 20 na Indeksu bolesti očne površine (OSDI);
iv.) rezultat Širmerovog testa I jednak ili veći od 2 mm, ali jednak ili manji od 8 mm.
9. Farmaceutska kompozicija za upotrebu prema bilo kom prethodnom patentnom zahtevu, gde je količina ciklosporina koja se primenjuje
i.) u jednoj dozi kompozicije po oku oko 10 μg, i/ili
ii.) u ukupnoj dnevnoj dozi kompozicije po oku oko 20 μg.
10. Farmaceutska kompozicija za upotrebu prema bilo kom prethodnom patentnom zahtevu, gde kompozicija sadrži do oko 1,0% (w/w) etanola.
11. Farmaceutska kompozicija za upotrebu prema bilo kom prethodnom patentnom zahtevu, gde kompozicija sadrži 2-perfluorobutil-pentan.
12. Farmaceutska kompozicija za upotrebu prema bilo kom prethodnom patentnom zahtevu, gde kompozicija sadrži oko 0,1% (mas/v) ciklosporina rastvorenog u 1-perfluorobutil-pentanu i do oko 1,0% (mas/mas) etanola, i gde je količina ciklosporina koja se primenjuje u jednoj dozi po oku oko 10 μg.
13. Farmaceutska kompozicija za upotrebu prema bilo kom prethodnom patentnom zahtevu, gde kompozicija sadrži oko 0,1% (mas/v) ciklosporina rastvorenog u 1-perfluorobutil-pentanu i do oko 1,0% (mas/mas) etanola, i pri čemu se količina ciklosporina primenjena u jednoj dozi po oku primenjuje u zapremini od oko 10 μl kompozicije.
14. Farmaceutska kompozicija za upotrebu prema bilo kom prethodnom patentnom zahtevu, gde kompozicija sadrži oko 0,1% (mas/v) ciklosporina rastvorenog u rastvoru od oko 99% (mas/mas) 1-perfluorobutil-pentana i oko 1,0% (mas/mas) etanola.
15. Komplet koji sadrži farmaceutsku kompoziciju za upotrebu prema bilo kom od patentnih zahteva 1 do 14, pri čemu komplet sadrži posudu za držanje farmaceutske kompozicije i dozator kapi prilagođen za davanje oko 10 μl zapremine kompozicije po kapi.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16206735 | 2016-12-23 | ||
| EP17165578 | 2017-04-07 | ||
| EP23212280.4A EP4374851B1 (en) | 2016-12-23 | 2017-12-20 | Ophthalmic composition for treatment of dry eye disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS68286B1 true RS68286B1 (sr) | 2026-07-31 |
Family
ID=61002978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20260802A RS68286B1 (sr) | 2016-12-23 | 2017-12-20 | Oftalmološka kompozicija za lečenje bolesti suvog oka |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180360908A1 (sr) |
| EP (3) | EP3777830B1 (sr) |
| JP (2) | JP7032404B2 (sr) |
| KR (1) | KR102288022B1 (sr) |
| CN (3) | CN110267645A (sr) |
| AU (1) | AU2017384650B2 (sr) |
| BR (1) | BR112019012791A2 (sr) |
| CA (1) | CA3045743C (sr) |
| DK (1) | DK3399962T3 (sr) |
| ES (3) | ES2965883T3 (sr) |
| HR (1) | HRP20260733T1 (sr) |
| MX (1) | MX381639B (sr) |
| PL (1) | PL3399962T3 (sr) |
| PT (1) | PT3399962T (sr) |
| RS (1) | RS68286B1 (sr) |
| SM (1) | SMT202600233T1 (sr) |
| WO (1) | WO2018115097A1 (sr) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| MX363182B (es) | 2012-09-12 | 2019-03-13 | Novaliq Gmbh | Composiciones que comprenden mezclas de alcanos semifluorados. |
| EP2895144B1 (en) | 2012-09-12 | 2017-01-11 | Novaliq GmbH | Semifluorinated alkane compositions |
| DK3024484T3 (en) | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
| US20170087100A1 (en) | 2015-09-30 | 2017-03-30 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| EP3722274B1 (en) | 2015-09-30 | 2023-06-07 | Novaliq GmbH | 2-perfluorobutyl pentane for ophthalmic administration |
| DK3442480T3 (da) | 2016-06-23 | 2020-01-13 | Novaliq Gmbh | Fremgangsmåde til topisk indgivelse |
| KR102614858B1 (ko) | 2016-09-22 | 2023-12-18 | 노바리크 게엠베하 | 안검염 치료에 사용되는 약제학적 조성물 |
| AU2017329983B2 (en) | 2016-09-23 | 2022-05-05 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| MX381639B (es) * | 2016-12-23 | 2025-03-13 | Novaliq Gmbh | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| JP7814839B2 (ja) | 2017-09-27 | 2026-02-17 | ノバリック ゲーエムベーハー | 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| AU2019246035B2 (en) | 2018-03-28 | 2024-07-18 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| JP7855312B2 (ja) | 2018-04-27 | 2026-05-08 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| US12472162B2 (en) * | 2018-07-24 | 2025-11-18 | Carefusion 213, Llc | Ready-to-use, terminally sterile packaging for surgical antiseptic and method of use |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| WO2020239646A1 (en) * | 2019-05-24 | 2020-12-03 | Novaliq Gmbh | Ophthalmic composition for the treatment of ocular allergy |
| CN114449999A (zh) * | 2019-09-06 | 2022-05-06 | 诺瓦利克有限责任公司 | 用于治疗葡萄膜炎的眼用组合物 |
| EP3861857A1 (en) * | 2020-02-07 | 2021-08-11 | Novaliq GmbH | Antiparasitic compositions |
Family Cites Families (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2616927A (en) | 1950-05-12 | 1952-11-04 | Minnesota Mining & Mfg | Fluorocarbon tertiary amines |
| US4452818A (en) | 1982-03-19 | 1984-06-05 | Haidt Sterling J | Extraocular method of treating the eye with liquid perfluorocarbons |
| US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
| JPS6452722A (en) | 1987-05-01 | 1989-02-28 | Anjierini Pharmaceut Inc | Ophthalmic composition |
| CH679210A5 (sr) | 1988-10-26 | 1992-01-15 | Sandoz Ag | |
| US6458376B1 (en) | 1990-09-27 | 2002-10-01 | Allergan, Inc. | Nonaqueous fluorinated drug delivery suspensions |
| US5518731A (en) | 1990-09-27 | 1996-05-21 | Allergan, Inc. | Nonaqueous fluorinated drug delivery vehicle suspensions |
| US5326566A (en) | 1991-05-17 | 1994-07-05 | Bristol-Myers Squibb Company | Use of dibutyl adipate and isopropyl myristate in topical and transdermal products |
| GB9114374D0 (en) | 1991-07-03 | 1991-08-21 | Smithkline Beecham Plc | Novel process |
| FR2679150A1 (fr) | 1991-07-17 | 1993-01-22 | Atta | Preparations comprenant un fluorocarbure ou compose hautement fluore et un compose organique lipophile-fluorophile, et leurs utilisations. |
| US6602900B2 (en) | 1992-09-21 | 2003-08-05 | Allergan, Inc. | Cyclopentane heptan(ENE)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
| US5336175A (en) | 1992-10-29 | 1994-08-09 | Mames Robert N | Method for the treatment of retinal detachments |
| US5370313A (en) | 1994-01-10 | 1994-12-06 | Beard; Walter C. | Sterile liquid dispenser |
| DE4405627A1 (de) | 1994-02-22 | 1995-08-24 | Hoechst Ag | Fluorkohlenwasserstoffe enthaltende Ölemulsionen |
| FR2720943B1 (fr) | 1994-06-09 | 1996-08-23 | Applic Transferts Technolo | Emulsions inverses stables à forte concentration en composé(s) fluoré(s) et leur utilisation pour l'administration pulmonaire de médicaments et pour la fabrication d'émulsions multiples. |
| US6294563B1 (en) | 1994-10-27 | 2001-09-25 | Allergan Sales, Inc. | Combinations of prostaglandins and brimonidine or derivatives thereof |
| US5696164A (en) | 1994-12-22 | 1997-12-09 | Johnson & Johnson Consumer Products, Inc. | Antifungal treatment of nails |
| US5667809A (en) | 1995-06-07 | 1997-09-16 | Alliance Pharmaceutical Corp. | Continuous fluorochemical microdispersions for the delivery of lipophilic pharmaceutical agents |
| US5874481A (en) | 1995-06-07 | 1999-02-23 | Alliance Pharmaceutical Corp. | Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents |
| US5578020A (en) | 1995-09-01 | 1996-11-26 | Mosley; Manuel L. | Drop dispensing apparatus |
| DE19536504C2 (de) | 1995-09-29 | 1999-09-23 | H Meinert | Verwendung fluorierter Alkane |
| US5874469A (en) | 1996-01-05 | 1999-02-23 | Alcon Laboratories, Inc. | Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs |
| US5704906A (en) | 1996-02-26 | 1998-01-06 | Fox; Richard L. | Method of using a topical anesthetic-cleaning solution and applicator |
| FR2752161B1 (fr) | 1996-08-07 | 1998-09-25 | Atta | Emulsions multiples de type hydrocarbure-dans-eau-dans- fluorocarbone pour le transport de substances medicamenteuses hydrophiles et/ou lipophiles |
| US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| IN184589B (sr) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| DE19709704C2 (de) | 1997-03-10 | 1999-11-04 | Michael Georgieff | Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie |
| US5980936A (en) | 1997-08-07 | 1999-11-09 | Alliance Pharmaceutical Corp. | Multiple emulsions comprising a hydrophobic continuous phase |
| US6645963B2 (en) | 1997-11-05 | 2003-11-11 | Senju Pharmaceutical Co., Ltd. | Prolonged-action eye drop |
| US5981607A (en) | 1998-01-20 | 1999-11-09 | Allergan | Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers |
| CA2278328C (en) | 1998-02-09 | 2008-07-22 | Macrochem Corporation | Antifungal nail lacquer and method using same |
| DE19861012A1 (de) | 1998-03-18 | 1999-09-30 | Pharm Pur Gmbh | Behandlungsmittel für die Ophthalmologie |
| CN1221249C (zh) | 1998-08-19 | 2005-10-05 | 斯凯伊药品加拿大公司 | 普鲁泊福的可注射水分散体 |
| US6140374A (en) | 1998-10-23 | 2000-10-31 | Abbott Laboratories | Propofol composition |
| US6159977A (en) | 1998-11-16 | 2000-12-12 | Astan, Inc. | Therapeutic anti-fungal nail preparation |
| EP1152749B1 (en) | 1999-02-08 | 2006-04-12 | ALZA Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| US7258869B1 (en) | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
| WO2000054588A1 (en) | 1999-03-15 | 2000-09-21 | John Claude Krusz | Treatment of acute headaches and chronic pain using rapidly-cleared anesthetic drug at sub-anesthetic dosages |
| US6177477B1 (en) | 1999-03-24 | 2001-01-23 | American Home Products Corporation | Propofol formulation containing TRIS |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| DE19926890C1 (de) | 1999-06-12 | 2000-07-27 | Pharm Pur Gmbh | Verwendung eines hochfluorierten oligomeren Alkans in der Ophthalmologie |
| DE19938668B4 (de) | 1999-08-14 | 2006-01-26 | Bausch & Lomb Inc. | Tränenersatzmittel |
| US6528086B2 (en) | 1999-09-28 | 2003-03-04 | Zars, Inc. | Methods and apparatus for drug delivery involving phase changing formulations |
| JP2001158734A (ja) | 1999-12-02 | 2001-06-12 | Lion Corp | 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法 |
| US20030018044A1 (en) | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| DE10024413A1 (de) | 2000-05-19 | 2001-12-06 | Mika Pharma Gmbh | Pharmazeutische und/oder kosmetische Zubereitung |
| US6399087B1 (en) | 2000-12-20 | 2002-06-04 | Amphastar Pharmaceuticals, Inc. | Propofol formulation with enhanced microbial inhibition |
| WO2002089849A1 (en) | 2001-05-07 | 2002-11-14 | Corium International | Compositions and delivery systems for administration of a local anesthetic agent |
| TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
| US20040265362A1 (en) | 2001-09-04 | 2004-12-30 | Rudy Susilo | Plaster for the treatment of dysfunctions and disorders of nail growth |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| US7074827B2 (en) | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
| AU2003275816A1 (en) | 2002-11-13 | 2004-06-03 | Cesar Augusto Cely Lizcano | A device and method for facilitating the application of liquid material to the eye |
| EP1663148A2 (en) | 2003-08-25 | 2006-06-07 | Foamix Ltd. | Penetrating pharmaceutical foam |
| US20050079210A1 (en) | 2003-10-09 | 2005-04-14 | Gupta Shyam K. | Liposomal delivery system for topical pharmaceutical, cosmeceutical, and cosmetic ingredients |
| CA2538856C (en) | 2003-10-10 | 2010-06-29 | Antares Pharma Ipl Ag | Transdermal pharmaceutical formulation for minimizing skin residues |
| CA2540621A1 (en) | 2003-11-19 | 2005-06-09 | Barnes-Jewish Hospital | Enhanced drug delivery |
| GB0408164D0 (en) | 2004-04-13 | 2004-05-19 | Immune Targeting Systems Ltd | Antigen delivery vectors and constructs |
| US20080019926A1 (en) | 2004-04-19 | 2008-01-24 | Marie-Pierre Krafft | Lung Surfactant Supplements |
| EP1763336A1 (en) | 2004-06-08 | 2007-03-21 | Ocularis Pharma, Inc. | Hydrophobic ophthalmic compositions and methods of use |
| US7063241B2 (en) | 2004-06-10 | 2006-06-20 | Allergan, Inc. | Dispensing tip |
| AU2005262392A1 (en) | 2004-07-01 | 2006-01-19 | Johnson & Johnson Vision Care, Inc. | Compositions and methods for treating eye disorders and conditions |
| US7740875B2 (en) | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
| EP1688161A1 (en) | 2004-11-02 | 2006-08-09 | Switch Biotech Aktiengesellschaft | Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis |
| US7851504B2 (en) | 2005-03-16 | 2010-12-14 | Allergan, Inc. | Enhanced bimatoprost ophthalmic solution |
| GB0511499D0 (en) | 2005-06-06 | 2005-07-13 | Medpharm Ltd | Topical ungual formulations |
| BRPI0614084A2 (pt) | 2005-08-05 | 2011-03-09 | Bharat Serums And Vaccines Limited | composição estável de emulsão de óleo-em-água de propofol, administrável por via intranovesa; e processo de preparação de uma composição |
| FR2892023B1 (fr) | 2005-10-14 | 2009-09-25 | Galderma Sa | Composition pharmaceutique a base d'amorolfine et d'agent filmogene hydrosoluble pour application ungueale et peri-ungueale |
| DE102005055811A1 (de) | 2005-11-23 | 2007-05-31 | Novaliq Gmbh | Verwendung einer Zusammensetzung zur Konservierung von Organen und Gliedmaßen |
| TWI376239B (en) | 2006-02-01 | 2012-11-11 | Andrew Xian Chen | Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof |
| WO2008011836A2 (es) | 2006-07-25 | 2008-01-31 | Osmotica Corp. | Soluciones oftálmicas |
| US20080039807A1 (en) | 2006-08-08 | 2008-02-14 | Jerrold Scott Pine | Ophthalmic Drug Dispensing Tip |
| US20080089923A1 (en) | 2006-09-29 | 2008-04-17 | Burkstrand Michael J | Biodegradable ocular implants and methods for treating ocular conditions |
| US9000048B2 (en) | 2006-11-28 | 2015-04-07 | Wisconsin Alumni Research Foundation | Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics |
| KR20090087917A (ko) | 2006-12-07 | 2009-08-18 | 썬 파마 어드밴스트 리서치 컴패니 리미티드 | 마이크로리터량의 액체를 방울의 형태로 분배하기 위한 계량된 방울 병 |
| EP2178502A2 (en) | 2007-06-21 | 2010-04-28 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
| FR2918891B1 (fr) | 2007-07-20 | 2009-09-25 | Thea Sa Lab | Solution ophtalmique a base de prostaglandines sans conservateur |
| US8222292B2 (en) | 2007-08-06 | 2012-07-17 | Insys Therapeutics, Inc. | Liquid cannabinoid formulations |
| DE102007055046A1 (de) | 2007-11-19 | 2009-05-28 | Fluoron Gmbh | Infusionslösung |
| CA2711696C (en) | 2008-01-09 | 2021-10-26 | Reza Dana | Therapeutic compositions for treatment of ocular inflammatory disorders |
| PL2110126T3 (pl) | 2008-04-18 | 2012-04-30 | Novaliq Gmbh | Zastosowanie do inhalacji i zakraplania semifluorowanych alkanów jako nośników substancji aktywnych w strefie wewnątrzpłucnej |
| US20100006600A1 (en) | 2008-07-14 | 2010-01-14 | Dascanio Gustavo A | Fluid dispenser including hydrophobic ring |
| JP2012509737A (ja) | 2008-11-26 | 2012-04-26 | サーモディクス,インコーポレイティド | 埋め込み式の眼薬送達器具および眼薬送達方法 |
| US8501800B2 (en) | 2009-03-05 | 2013-08-06 | Insite Vision Incorporated | Controlled-release ophthalmic vehicles |
| IT1393419B1 (it) | 2009-03-19 | 2012-04-20 | Medivis S R L | Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6. |
| WO2010127301A1 (en) | 2009-05-01 | 2010-11-04 | Allergan, Inc. | Method of treating allergic conjunctivitis with cyclosporin compositions |
| WO2010146536A1 (en) | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
| JP5549669B2 (ja) | 2009-06-25 | 2014-07-16 | ライオン株式会社 | 眼科用組成物、ドライアイ治療剤及びビタミンaの安定化方法 |
| JP5736635B2 (ja) | 2009-06-25 | 2015-06-17 | ライオン株式会社 | ドライアイ治療剤 |
| PT2387391T (pt) | 2009-07-24 | 2017-04-20 | Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh | Processo para o desenvolvimento de uma composição líquida a ser aplicada na forma de espuma sobre a pele e composição de aplicação tópica |
| JP2011024841A (ja) | 2009-07-28 | 2011-02-10 | 健太 ▲浜崎▼ | 点眼補助具 |
| EP2332525A1 (en) | 2009-11-23 | 2011-06-15 | Novaliq GmbH | Pharmaceutical composition comprising propofol |
| EP2335735A1 (en) * | 2009-12-14 | 2011-06-22 | Novaliq GmbH | Pharmaceutical composition for treatment of dry eye syndrome |
| US20110223208A1 (en) | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| ES2564502T3 (es) | 2010-03-17 | 2016-03-23 | Novaliq Gmbh | Composición farmacéutica para el tratamiento de la presión intraocular aumentada |
| DE102010022567A1 (de) | 2010-06-02 | 2011-12-08 | Fluoron Gmbh | Zubereitung |
| EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| EP2661280B1 (en) | 2011-01-04 | 2018-11-21 | Novaliq GmbH | O/w-emulsions comprising semifluorinated alkanes |
| CN103561724B (zh) | 2011-05-25 | 2016-06-29 | 诺瓦利克有限责任公司 | 给药给甲的药物组合物 |
| JP6039145B2 (ja) | 2011-05-25 | 2016-12-07 | ノバリック ゲーエムベーハー | 半フッ化アルカンを基礎にした局所薬学的組成物 |
| PT2806886T (pt) | 2012-01-23 | 2017-03-24 | Novaliq Gmbh | Composições de proteínas estabilizadas baseadas em alcanos semifluorados |
| WO2013126602A1 (en) * | 2012-02-21 | 2013-08-29 | Massachusetts Eye & Ear Infirmary | Inflammatory eye disorders |
| US9878000B2 (en) * | 2012-06-20 | 2018-01-30 | University Of Waterloo | Mucoadhesive nanoparticle composition comprising immunosuppresant and methods of use thereof |
| US10004714B2 (en) | 2012-07-09 | 2018-06-26 | Brien Holden Vision Institute | Compositions, methods and/or devices for prevention and/or treatment of dry eye disorders |
| EP2895144B1 (en) | 2012-09-12 | 2017-01-11 | Novaliq GmbH | Semifluorinated alkane compositions |
| MX363182B (es) * | 2012-09-12 | 2019-03-13 | Novaliq Gmbh | Composiciones que comprenden mezclas de alcanos semifluorados. |
| KR20150095684A (ko) * | 2012-12-18 | 2015-08-21 | 노파르티스 아게 | 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법 |
| EP2783703A1 (en) | 2013-03-25 | 2014-10-01 | B. Braun Melsungen AG | Semifluorocarbon compound containing contrast agent |
| DK3024484T3 (en) | 2013-07-23 | 2018-10-08 | Novaliq Gmbh | STABILIZED ANTIBODY COMPOSITIONS |
| AU2014332488B2 (en) | 2013-10-09 | 2017-03-09 | Johnson Living Trust Dated October 26, 2001, Leonidas A. Johnson, Trustee | Methods and compositions for treating and preventing signs or symptoms of eye disease |
| MX376125B (es) | 2014-03-31 | 2025-03-07 | Amcor Rigid Plastics Usa Llc | Recipiente de liberacion controlada. |
| EP2944324A1 (de) | 2014-05-13 | 2015-11-18 | LTS LOHMANN Therapie-Systeme AG | Verwendung von semifluorierten Alkanen in transdermalen therapeutischen Systemen |
| WO2016025560A1 (en) | 2014-08-13 | 2016-02-18 | University Of Florida Research Foundation, Inc. | Preservative removal from eye drops |
| US11285163B2 (en) | 2014-10-20 | 2022-03-29 | Sentiss Pharma Private Limited | Ophthalmic solution |
| WO2016082644A1 (en) | 2014-11-26 | 2016-06-02 | The University Of Hong Kong | A semifluorinated alkane based cleaner for removing emulsified droplets in the eye to reduce the complications associated with the emulsification of silicone oil |
| US20170087100A1 (en) * | 2015-09-30 | 2017-03-30 | Novaliq Gmbh | Semifluorinated compounds and their compositions |
| EP3722274B1 (en) | 2015-09-30 | 2023-06-07 | Novaliq GmbH | 2-perfluorobutyl pentane for ophthalmic administration |
| EP3362096B1 (en) | 2015-10-14 | 2023-12-13 | Paul Gavaris | Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents |
| JP2019517580A (ja) | 2016-06-01 | 2019-06-24 | ハロルド・リチャード・ヘルストロムHarold Richard HELLSTROM | 副交感神経薬および抗交感神経薬でのドライアイ疾患の処置 |
| DK3442480T3 (da) | 2016-06-23 | 2020-01-13 | Novaliq Gmbh | Fremgangsmåde til topisk indgivelse |
| KR102614858B1 (ko) | 2016-09-22 | 2023-12-18 | 노바리크 게엠베하 | 안검염 치료에 사용되는 약제학적 조성물 |
| AU2017329983B2 (en) | 2016-09-23 | 2022-05-05 | Novaliq Gmbh | Ophthalmic compositions comprising ciclosporin |
| WO2018114557A1 (en) | 2016-12-22 | 2018-06-28 | Novaliq Gmbh | Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases |
| MX381639B (es) | 2016-12-23 | 2025-03-13 | Novaliq Gmbh | Composicion oftalmica para el tratamiento de la enfermedad del ojo seco. |
| PL3612228T3 (pl) | 2017-04-21 | 2024-04-08 | Dermaliq Therapeutics, Inc. | Kompozycje jodu |
| US20210069014A1 (en) | 2017-05-06 | 2021-03-11 | Novaliq Gmbh | Drop dispenser |
| US11278503B2 (en) | 2017-05-12 | 2022-03-22 | Novaliq Gmbh | Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions |
| JP7814839B2 (ja) | 2017-09-27 | 2026-02-17 | ノバリック ゲーエムベーハー | 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物 |
| CN111182893A (zh) | 2017-10-04 | 2020-05-19 | 诺瓦利克有限责任公司 | 包含f6h8的眼用组合物 |
| US11576893B2 (en) | 2018-03-02 | 2023-02-14 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
| AU2019246035B2 (en) | 2018-03-28 | 2024-07-18 | Novaliq Gmbh | Pharmaceutical composition comprising timolol |
| JP7855312B2 (ja) | 2018-04-27 | 2026-05-08 | ノバリック ゲーエムベーハー | 緑内障の治療のためのタフルプロストを含む眼科用組成物 |
| EP3852734A1 (en) | 2018-09-22 | 2021-07-28 | Novaliq GmbH | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness |
| WO2020064549A1 (en) | 2018-09-27 | 2020-04-02 | Novaliq Gmbh | Lipid barrier repair |
| US11510855B2 (en) | 2018-09-27 | 2022-11-29 | Dermaliq Therapeutics, Inc. | Topical sunscreen formulation |
| CA3112031A1 (en) | 2018-10-12 | 2020-04-16 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
| CN113164609A (zh) | 2018-11-27 | 2021-07-23 | 诺瓦利克有限责任公司 | 包含ω-3脂肪酸乙酯的半氟化烷烃组合物 |
| CN113518619A (zh) | 2019-01-21 | 2021-10-19 | 诺瓦利克有限责任公司 | 用于治疗眼部新生血管形成的药物组合物 |
| EP3923907B1 (en) | 2019-02-13 | 2024-09-25 | Novaliq GmbH | Compositions and methods for the treatment of ocular neovascularization |
| WO2020239646A1 (en) | 2019-05-24 | 2020-12-03 | Novaliq Gmbh | Ophthalmic composition for the treatment of ocular allergy |
| JP2022543402A (ja) | 2019-08-09 | 2022-10-12 | ノバリック ゲーエムベーハー | プロスタグランジンアナログを含む局所組成物 |
| CN114449999A (zh) | 2019-09-06 | 2022-05-06 | 诺瓦利克有限责任公司 | 用于治疗葡萄膜炎的眼用组合物 |
| EP4065082A1 (en) | 2019-11-27 | 2022-10-05 | Novaliq GmbH | Suspension comprising a protein particle suspended in a non-aqueous vehicle |
-
2017
- 2017-12-20 MX MX2019007587A patent/MX381639B/es unknown
- 2017-12-20 EP EP20178792.6A patent/EP3777830B1/en active Active
- 2017-12-20 CN CN201780079941.0A patent/CN110267645A/zh active Pending
- 2017-12-20 EP EP23212280.4A patent/EP4374851B1/en active Active
- 2017-12-20 AU AU2017384650A patent/AU2017384650B2/en active Active
- 2017-12-20 WO PCT/EP2017/083770 patent/WO2018115097A1/en not_active Ceased
- 2017-12-20 HR HRP20260733TT patent/HRP20260733T1/hr unknown
- 2017-12-20 KR KR1020197021384A patent/KR102288022B1/ko active Active
- 2017-12-20 PT PT178320669T patent/PT3399962T/pt unknown
- 2017-12-20 EP EP17832066.9A patent/EP3399962B1/en active Active
- 2017-12-20 CN CN202610212360.0A patent/CN122057006A/zh active Pending
- 2017-12-20 CN CN202610216822.6A patent/CN122005753A/zh active Pending
- 2017-12-20 SM SM20260233T patent/SMT202600233T1/it unknown
- 2017-12-20 ES ES20178792T patent/ES2965883T3/es active Active
- 2017-12-20 BR BR112019012791-7A patent/BR112019012791A2/pt not_active Application Discontinuation
- 2017-12-20 PL PL17832066T patent/PL3399962T3/pl unknown
- 2017-12-20 JP JP2019533180A patent/JP7032404B2/ja active Active
- 2017-12-20 DK DK17832066.9T patent/DK3399962T3/da active
- 2017-12-20 ES ES23212280T patent/ES3071053T3/es active Active
- 2017-12-20 CA CA3045743A patent/CA3045743C/en active Active
- 2017-12-20 ES ES17832066T patent/ES2819005T3/es active Active
- 2017-12-20 RS RS20260802A patent/RS68286B1/sr unknown
-
2018
- 2018-08-22 US US16/109,127 patent/US20180360908A1/en not_active Abandoned
-
2021
- 2021-12-31 JP JP2021215498A patent/JP2022050514A/ja not_active Withdrawn
-
2022
- 2022-09-19 US US17/933,471 patent/US12496326B2/en active Active
-
2025
- 2025-12-09 US US19/413,977 patent/US20260091084A1/en active Pending